Prevalence and Characteristics of Pneumonitis Following Irradiation of Breast Cancer

Background/Aim: Pneumonitis is a serious complication after radiotherapy of breast cancer. This study aimed to identify its prevalence and potential risk factors. Patients and Methods: A total of 606 patients irradiated following breast-conserving surgery or mastectomy were retrospectively analyzed....

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-11, Vol.39 (11), p.6355-6358
Main Authors: WERNER, ELISA M., EGGERT, MARIE C., BOHNET, SABINE, RADES, DIRK
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapies
Chemotherapy
Health risk assessment
Identification methods
Inflammatory diseases
Irradiation
Lungs
Malignancy
Medical treatment
Monoclonal antibodies
Ovarian cancer
Parameter identification
Patients
Pneumonitis
Radiation
Radiation dosage
Radiation therapy
Risk analysis
Risk factors
Surgery
Targeted cancer therapy
Taxanes
Thyroid
Thyroid cancer
Trastuzumab
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: Pneumonitis is a serious complication after radiotherapy of breast cancer. This study aimed to identify its prevalence and potential risk factors. Patients and Methods: A total of 606 patients irradiated following breast-conserving surgery or mastectomy were retrospectively analyzed. In patients developing pneumonitis, radiation and clinical parameters were investigated to identify potential risk factors. Results: Eleven patients (1.8%) developed a pneumonitis grade ≥2. Mean doses to the ipsilateral lung were >7 Gy in 5 patients (45%). Of the other patients, 5 had a chronic inflammatory disease. Six patients (55%) had another malignancy (4 previous contralateral breast cancers, 1 previous ovarian and thyroid cancer, 1 synchronous carcinoma-in-situ (pTis) at the contralateral breast). Five patients (45%) received chemotherapy including taxanes and 4 patients (36%) received trastuzumab. Conclusion: The prevalence of pneumonitis was 1.8%. Potential risk factors included mean radiation dose to ipsilateral lung >7 Gy, systemic treatment with taxanes or trastuzumab, chronic inflammatory disease and history of another malignancy.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13847